Splenectomy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:28:08 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Splenectomy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Immune Response of Meningococcal B Vaccine in Adults Without a Spleen https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-meningococcal-b-vaccine-in-adults-without-a-spleen/ Wed, 29 Apr 2026 15:05:26 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-meningococcal-b-vaccine-in-adults-without-a-spleen/ This clinical trial is focused on studying the effects of a vaccine called Bexsero in adults who have had their spleen removed, a condition known as asplenia. The vaccine is designed to protect against a type of bacteria called Neisseria meningitidis group B, which can cause serious infections. The study aims to see if the vaccine works as well in people without a spleen as it does in healthy individuals.

Participants in the study will receive the Bexsero vaccine through an injection into the muscle. The study will involve two vaccinations, and the main focus is to measure the body’s immune response one month after the second vaccination. This will be done by checking the levels of protective antibodies in the blood. The study will also look at how long these antibodies last and will monitor any side effects that may occur after receiving the vaccine.

The goal of the study is to ensure that the vaccine provides adequate protection for people with asplenia, as they are at a higher risk for infections. The study will compare the immune response of these individuals to that of healthy people to determine if the vaccine is equally effective in both groups. Participants will be observed for any adverse events, and their immune response will be assessed through various tests.

]]>